The French drug maker reports a big rise in its dividend.
Sanofi-Aventis, headquartered in Paris, France, is a multinational pharmaceutical company. The company is one of the five largest pharmaceutical companies in the world. Sanofi-Aventis engages in the research, development, manufacturing and marketing of pharmaceutical products for sale principally in the prescription market, but they also develop over-the-counter medication. Sanofi-Aventis cover 7 major therapeutic areas: cardiovascular, thrombosis, oncology, diabetes, central nervous system, internal medicine and vaccines (with its subsidiary Sanofi Pasteur).
- Breakdown of share ownership: approximitly 13% by Total, 10.13% by L'Oréal, 5.47% treasury shares, 1.29% employees, the remaining 70.46% are publicly traded.
- Voting rights distribution: 21.37% to Total, 17.12% to L'Oréal, 1.54% to employees, and 59.97% to the public.
L'Oreal curtailed its stake in Sanofi-Aventis. Last year the stockholder sold 1.8 percent of Sanofi-Aventis, reducing its stake to 8.7 percent.
Total, the other main shareholder, reported that it’s going to sell the whole of its 13.1 percent stake by the end of 2012.
Sanofi-Aventis explains the growth of its dividents as a planned operation.
The company refuses to admit that the changes are connected with the actions of its main shareholders. Earlier Sanofi-Aventis said that it had planned to raise the dividend when the debt was at a reasonable level.
Russia, when signing documents for the sale of Alaska to the United States, was realizing her objective benefit
Putin's official spokesman Dmitry Peskov commented on remarks in the US media about failures in launching nuclear-capable missiles in Russia